Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 11/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632609 | 0.94 | L3MBTL1 (0.40) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632643 | 0.91 | L3MBTL1 (0.40) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632738 | 0.89 | L3MBTL1 (0.40) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632701 | 0.89 | L3MBTL1 (0.42) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632570 | 0.88 | L3MBTL1 (0.39) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632519 | 0.88 | L3MBTL1 (0.39) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL17883370 | 0.88 | L3MBTL1 (0.44) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632343 | 0.88 | L3MBTL1 (0.37) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632516 | 0.84 | L3MBTL1 (0.40) | L3MBTL1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16632520 | 0.82 | L3MBTL1 (0.49) | L3MBTL1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885MAPT 1046/4885MEN1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.